Nonsteroidal anti-inflammatory drug-induced reactions and desensitization (Q28209835)

Aspirin desensitization in patients with AERD

Europe PubMed Central

title

Nonsteroidal anti-inflammatory drug-induced reactions and desensitization (English)

0 references

1 reference

M Pilar Berges-Gimeno

series ordinal

1

0 references

Donald D Stevenson

series ordinal

2

0 references

language of work or name

English

0 references

publication date

June 2004

0 references

published in

Journal of Asthma

0 references

volume

41

0 references

issue

4

0 references

page(s)

375-84

0 references

cites work

1 reference

https://api.crossref.org/works/10.1081/JAS-120037650

Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma

21 April 2017

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

The mode of action of aspirin and similar compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Pulmonary infiltrates associated with sulindac therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

The natural history and clinical characteristics of aspirin-exacerbated respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Long-term prognosis of near-fatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Intolerance to aspirin. Clinical studies and consideration of its pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Salsalate cross-sensitivity in aspirin-sensitive patients with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Safety of a specific COX-2 inhibitor in aspirin-induced asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

The safety of celecoxib in patients with aspirin-sensitive asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Tolerability of rofecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Rofecoxib safe in NSAID hypersensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Celecoxib, safe in NSAID intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Refractory period to aspirin in a patient with aspirin-induced asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Asthma relieved by aspirin and by other cyclo-oxygenase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650

Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FJAS-120037650